NASDAQ$SXTC
China SXT Pharmaceuticals Inc. · Q4 2024 earnings
Q4 2024 earnings · · Investor relations
Briefing
SXTC Q4 2024 — CNY 700.0M revenue
VIE pursuant to the certain contractual arrangements (the “VIE Agreements”), and can consolidate the financial results. China SXT Pharmaceuticals Inc. reported Q4 2024 results. Net income of CNY 5.9M. Headline numbers extracted from the Form 20-F press release; narrative is light because this row was processed without an LLM call.
- Revenue: CNY 700.0M.
- Net income: CNY 5.9M.
- Operating income: CNY 2.5M.
- Gross profit: CNY 554K.
Headline financials
Revenue & EPS history
China SXT · Revenue · Quarterly
$1.93M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q4 2024
-5.7%
Avg return
Earnings day
-14.5%
Avg return
5 days after
-25.4%
Avg return
30 days after
23%
3 / 13 earnings
Positive
+20.4%
Q2 2020
Best reaction
-59.0%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | -1.0% | -1.9% | -36.5% | |
| Q4 2023 | -1.0% | -100.0% | -100.0% | |
| Q2 2023 | -6.9% | -4.9% | -30.6% | |
| Q4 2022 | +2.7% | -13.4% | -17.1% | |
| Q2 2022 | -59.0% | -62.8% | -65.4% | |
| Q4 2021 | -10.5% | -9.7% | -10.5% | |
| Q2 2021 | +3.6% | +0.8% | +11.0% | |
| Q4 2020 | -6.7% | -1.2% | -25.0% | |
| Q2 2020 | +20.4% | +15.6% | +13.7% | |
| Q4 2019 | -5.0% | -4.8% | -18.6% | |
| Q4 2018 | -5.0% | -4.8% | -18.6% | |
| Q4 2017 | -5.0% | -4.8% | -18.6% | |
| Q2 2019 | -0.5% | +3.6% | -14.0% | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro